Skip to content

Local Analgesia in Knee- and Hipatroplastic Surgery in Patients With Rheumatic Disease: Extra- vs. Intracapsulare Position of Catheter

Local Analgesia in Knee- and Hipatroplastic Surgery in Patients With Rheumatic Disease: Extra- vs. Intracapsulare Position of Catheter

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01050738
Enrollment
72
Registered
2010-01-15
Start date
2010-01-31
Completion date
2010-08-31
Last updated
2010-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Orthopedic Surgery, Rheumatoid Arthritis

Brief summary

Postoperative pain is part of surgery trauma. In orthopedic surgery artroplastic replacement of knee- and hipjoints are common. Postoperative pain relieve can be complicated. A new concept for pain relieve postoperative is local infiltration analgesia (LIA). This technique implicates that a catheter is left in the surgical area and that local anestesia can be administered post surgery. The goal is no or only little pain with minimal side effects. The catheter could be placed intra- or extracapsulare. The best position is not known. Primary aim is to study if position of the catheter effects the need of other postoperative analgesia. Secondary aim is to study if the position effects patient mobility within the first two days.

Interventions

PROCEDUREPosition of catheter

Position of catheter for administration of local anestesia.

Sponsors

Spenshult Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients undergoing arthroplastic surgery of knee or hip

Exclusion criteria

* Sensitivity to local anesthetics * Other reason not to use local anesthetics

Design outcomes

Primary

MeasureTime frame
Need for other postoperative analgesia.48 hours

Secondary

MeasureTime frame
Patient mobility within the first 48 hours.48 hours

Countries

Sweden

Contacts

Primary ContactIgor Dobrydnjov, MD, PhD
igor.dobrydnjov@spenshult.se+46-352635000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026